This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n10http://dx.doi.org/10.1093/OFID/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q94127125
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в жовтні 2019 wetenschappelijk artikel article scientifique publié en 2019 im Oktober 2019 veröffentlichter wissenschaftlicher Artikel
p:P577
wds:Q94127125-7D72394E-F43B-49B6-A11F-0FD1F423338F
wdt:P577
2019-10-23T00:00:00Z
p:P2093
wds:Q94127125-3E7A041B-A734-4B0E-88F4-579B1B4EA721 wds:Q94127125-21FA8BCB-C8C0-4BEB-83E5-E8ED8267E3FF wds:Q94127125-26DEE0D6-7634-4D29-9812-F82B24ABDC48 wds:Q94127125-EBF10681-927B-4F4C-A6FF-FFDBF880B700 wds:Q94127125-BF706626-D9B6-4D34-8F80-48D236BEEE0F
wdt:P2093
Edward E Walsh Daniel Scott Beate Schmoele-Thoma David Radley Agnieszka Zareba
rdfs:label
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate 2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
skos:prefLabel
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate 2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
schema:name
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate 2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
p:P50
wds:Q94127125-042AC7FB-A53E-4535-B69B-E4A60CF295CC wds:Q94127125-722312C8-C819-43EB-A757-6BAAEF22EC17 wds:Q94127125-2D1633B8-A206-43DF-938B-536F9E8302F2 wds:Q94127125-90CFC71F-95EB-4AE3-A422-179ECC90147A wds:Q94127125-7C65F5F3-A505-4C9C-9248-31471713CCC2 wds:Q94127125-863A5D6B-4603-4D8E-AAD2-F3D1114CDCFD
wdt:P50
wd:Q106475090 wd:Q101423214 wd:Q91075894 wd:Q92382877 wd:Q98390154 wd:Q104936760
p:P1476
wds:Q94127125-E8477D28-6051-4061-8450-14BE71D4BF48
wdt:P1476
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
p:P304
wds:Q94127125-9A53010F-1D33-4686-AA27-815D7DBEFAC7
wdt:P304
S970-S970
p:P31
wds:Q94127125-368824BA-33F3-467C-B7D2-9C1F3425DD90
wdt:P31
wd:Q13442814
p:P1433
wds:Q94127125-66BC7C5A-8190-413E-8B96-13E45C6B02E7
wdt:P1433
wd:Q27725953
p:P433
wds:Q94127125-DD571336-A6E5-45BE-AC1C-90894EAAEE46
p:P478
wds:Q94127125-DE139DA9-1CB0-4E44-8D09-0A641E13AF0C
wdt:P433
Suppl 2
wdt:P478
6
p:P356
wds:Q94127125-7EE126AB-95B8-4ADD-9A39-DE6C73801538
wdtn:P356
n10:OFZ360.2432
wdt:P356
10.1093/OFID/OFZ360.2432
p:P275
wds:Q94127125-1c715b70-3d9f-45e3-8311-f6078314015d
p:P6216
wds:Q94127125-86784f69-f7ab-4967-93a0-611fb06cdf23
wdt:P275
wd:Q24082749
wdt:P6216
wd:Q50423863
p:P932
wds:Q94127125-61B79FFB-62D5-4661-BD4F-32BED8BC0C1B
wdt:P932
6809502